Safesnap Safety Syringe
by U.S. Medical Instruments, Inc. 510(k)
Active
510(k) K925039
Overview
The Safesnap Safety Syringe is a syringe, antistick device designed to reduce the risk of transmission of blood-borne diseases from accidental needle sticks in healthcare and home care settings. It is a single-use hypodermic syringe intended for general hospital use.
The device is supplied as a sterile, single-use product and is regulated under FDA 510(k) clearance K925039, with product code MEG and regulation number 880.5860. It was determined to be substantially equivalent to a predicate device and received traditional clearance on February 16, 1994.
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK925039 | Date16 Feb 1994 | StatusActive |
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not known
- Not covered
United States — FDA 510(k) Active
Recalls
No FDA recalls on record, checked 22 Oct 2026.
Specification
- 510(k) Number
- FDA Product Code
- MEG
- Device Class
- Class II
- Regulation
- 21 CFR Part 880.5860
- Advisory Committee
- General Hospital
- FDA Decision
- SESE Substantially Equivalent
Other devices from U.S. Medical Instruments, Inc.
Questions
What is the Safesnap Safety Syringe used for?
The Safesnap Safety Syringe is designed to reduce the risk of transmission of blood-borne diseases from accidental needle sticks in healthcare and home care settings by incorporating an antistick mechanism that activates after use.
Is the Safesnap Safety Syringe sterile and single-use?
Yes, the device is supplied as a sterile, single-use product, meaning it is intended for one-time use only and should be discarded after each injection to maintain sterility and prevent cross-contamination.
What regulatory pathway was used for the Safesnap Safety Syringe?
The Safesnap Safety Syringe received FDA 510(k) clearance under K925039, determined to be substantially equivalent to a predicate device, and was cleared via the traditional pathway on February 16, 1994.